Table 2 Breakdown of primary outcome phenotypes associated with stress exposure in adolescent rodents (n = 60).
Outcome measure | Total number of studies measuring the outcome of interest (% total studies with specific outcome of significant increase ▴ or decrease ▾) | Number of studies with specific outcome of ▴Significantly increaseda ▾Significantly decreaseda - No significant differencea | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UCMS/CMS/ CVS (n = 47) | Restraint Stress (n = 7) | CSDS/SDS/RSDS (n = 4) | Maternal Stress (n = 2) | ||||||||||
▴ | ▾ | - | ▴ | ▾ | - | ▴ | ▾ | - | ▴ | ▾ | - | ||
Pro-inflammatory cytokines – protein levels | |||||||||||||
IL-1β | 48 (▴98%) | 42 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
IL-1β (cleaved) | 1 (▴100%) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IL-6 | 45 (▴93%) | 33 | 0 | 1 | 6 | 0 | 1 | 4 | 0 | 2 | 1 | 0 | 0 |
IL-8 | 1 (▴100%) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IL-17A | 1 (▴100%) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IL-18 | 8 (▴100%) | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IL-33 | 1 (▴0%) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MCP-1 | 2 (▴100%) | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TNF-α | 49 (▴98%) | 39 | 0 | 0 | 6 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 0 |
Pro-inflammatory cytokines – RNA levels | |||||||||||||
IL-1β | 18 (▴100%) | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
IL-6 | 12 (▴100%) | 10 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
IL-18 | 5 (▴100%) | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CCL-1 | 3 (▴100%) | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CCL-2 | 1 (▴100%) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CXCL-1 | 3 (▴100%) | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TNF-α | 20 (▴95%) | 16 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
Anti-inflammatory cytokines – protein levels | |||||||||||||
IL-1ra | 1 (▾100%) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IL-9 | 1 (▾0%) | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IL-10 | 7 (▾100%) | 0 | 6 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IL-24 | 1 (▾0%) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IL-37 | 1 (▾0%) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TGF-β | 2 (▾100%) | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Anti-inflammatory cytokines – RNA levels | |||||||||||||
IL-10 | 6 (▾67%) | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TGF-β | 4 (▾50%) | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cytokines that have both pro-inflammatory and anti-inflammatory properties – protein levels | |||||||||||||
CX3CL1 | 2 (▴0%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
CXCL12 | 1 (▴100%) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TH1 cytokines – protein levels | |||||||||||||
IFN-β | 1 (▴100%) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IFNγ | 2 (▴50%) | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
TH1 cytokines – RNA levels | |||||||||||||
IFNγ | 1 (▴100%) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TH2 cytokines – protein levels | |||||||||||||
IL-4 | 2 (▾50%) | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TH2 cytokines – RNA levels | |||||||||||||
IL-4 | 5 (▾20%) | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |